Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · IEX Real-Time Price · USD
2.84
-0.13 (-4.38%)
May 31, 2023, 4:00 PM EDT - Market closed
Company Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders.
Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.
The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD |
Contact Details
Address:
2222 Ponce De Leon Blvd. 3rd Floor Coral Gables, Florida 33134 United States | |
| Phone | 646 876 3459 |
| Website | relmada.com |
Stock Details
| Ticker Symbol | RLMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553643 |
| CUSIP Number | 75955J402 |
| ISIN Number | US75955J4022 |
| Employer ID | 45-5401931 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD | Chief Executive Officer and Director |
| Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph. | Chief Financial Officer |
| Charles S. Ence CPA, M.B.A. | Chief Accounting and Compliance Officer |
| Dr. Paolo Manfredi M.D., Ph.D. | Chief Scientific Officer |
| Gina DiGuglielmo | Vice President and Head of Clinical Operations |
| Dr. Marco Pappagallo M.D. | Chief Medical Officer |
| John Hixon | Head of Commercial |
| Dr. Richard M. Mangano | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 25, 2023 | 8-K | Current Report |
| May 15, 2023 | 8-K | Current Report |
| May 11, 2023 | 8-K | Current Report |
| May 11, 2023 | 10-Q | Quarterly Report |
| Apr 19, 2023 | 8-K | Current Report |
| Mar 31, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2023 | DEF 14A | Other definitive proxy statements |
| Mar 23, 2023 | 10-K | Annual Report |
| Mar 23, 2023 | 8-K | Current Report |
| Mar 13, 2023 | 8-K | Current Report |